Sustained release and stabilization of therapeutic antibodies using amphiphilic polyanhydride nanoparticles

Brenda R. Carrillo-Conde, Ross J. Darling, Steven J. Seiler, Amanda E. Ramer-Tait, Michael J. Wannemuehler, Balaji Narasimhan

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Passive administration of antibodies (e.g., anti-serum or monoclonal antibodies) can be successfully used as treatments for infectious agents (e.g., human cytomegalovirus, HIV), chronic inflammation (e.g., anti-TNF), cancer (e.g., anti-HER2, anti-VEGF, anti-CD20), toxins (e.g., anti-ricin), and age-related diseases such as macular degeneration (e.g., anti-VEGF). As with the development of proteinaceous pharmaceuticals, one of the most challenging obstacles facing passive immunotherapies is the physical and the chemical instabilities of the antibodies, which invariably leads to loss of biological activity. In order to avoid these problems, appropriate delivery vehicles need to be designed that minimize the degradation, maximize the in vivo activity, and provide controlled release of the encapsulated biologically active protein. In this study, polyanhydride nanoparticles were used for the delivery of stable and biologically active therapeutic antibodies. Tetanus antitoxin and anti-TNF-α monoclonal antibodies were encapsulated and released from polyanhydride nanoparticles. The nanoparticles provided the ability to control antibody release kinetics and, additionally, preserved antibody functionality and bioactivity upon synthesis and release. In particular, amphiphilic polyanhydride nanoparticles demonstrated the best combination of characteristics compatible for anti-serum or monoclonal antibody preservation and release, making them ideal candidates for use as a delivery system for therapeutic antibodies.

Original languageEnglish (US)
Pages (from-to)98-107
Number of pages10
JournalChemical Engineering Science
Volume125
DOIs
StatePublished - Mar 4 2015

Fingerprint

Polyanhydrides
Antibody
Antibodies
Nanoparticles
Stabilization
Monoclonal antibodies
Monoclonal Antibody
Tumor Necrosis Factor
Monoclonal Antibodies
Bioactivity
Vascular Endothelial Growth Factor A
Tetanus Antitoxin
Immunotherapy
Inflammation
Pharmaceuticals
Degeneration
Preservation
Drug products
Cancer
Degradation

Keywords

  • Delivery
  • Nanoparticles
  • Polyanhydrides
  • Stability
  • Therapeutic antibodies

ASJC Scopus subject areas

  • Chemistry(all)
  • Chemical Engineering(all)
  • Industrial and Manufacturing Engineering
  • Applied Mathematics

Cite this

Sustained release and stabilization of therapeutic antibodies using amphiphilic polyanhydride nanoparticles. / Carrillo-Conde, Brenda R.; Darling, Ross J.; Seiler, Steven J.; Ramer-Tait, Amanda E.; Wannemuehler, Michael J.; Narasimhan, Balaji.

In: Chemical Engineering Science, Vol. 125, 04.03.2015, p. 98-107.

Research output: Contribution to journalArticle

Carrillo-Conde, Brenda R. ; Darling, Ross J. ; Seiler, Steven J. ; Ramer-Tait, Amanda E. ; Wannemuehler, Michael J. ; Narasimhan, Balaji. / Sustained release and stabilization of therapeutic antibodies using amphiphilic polyanhydride nanoparticles. In: Chemical Engineering Science. 2015 ; Vol. 125. pp. 98-107.
@article{086cca8aaf1949c0aa10d11f5d6d78eb,
title = "Sustained release and stabilization of therapeutic antibodies using amphiphilic polyanhydride nanoparticles",
abstract = "Passive administration of antibodies (e.g., anti-serum or monoclonal antibodies) can be successfully used as treatments for infectious agents (e.g., human cytomegalovirus, HIV), chronic inflammation (e.g., anti-TNF), cancer (e.g., anti-HER2, anti-VEGF, anti-CD20), toxins (e.g., anti-ricin), and age-related diseases such as macular degeneration (e.g., anti-VEGF). As with the development of proteinaceous pharmaceuticals, one of the most challenging obstacles facing passive immunotherapies is the physical and the chemical instabilities of the antibodies, which invariably leads to loss of biological activity. In order to avoid these problems, appropriate delivery vehicles need to be designed that minimize the degradation, maximize the in vivo activity, and provide controlled release of the encapsulated biologically active protein. In this study, polyanhydride nanoparticles were used for the delivery of stable and biologically active therapeutic antibodies. Tetanus antitoxin and anti-TNF-α monoclonal antibodies were encapsulated and released from polyanhydride nanoparticles. The nanoparticles provided the ability to control antibody release kinetics and, additionally, preserved antibody functionality and bioactivity upon synthesis and release. In particular, amphiphilic polyanhydride nanoparticles demonstrated the best combination of characteristics compatible for anti-serum or monoclonal antibody preservation and release, making them ideal candidates for use as a delivery system for therapeutic antibodies.",
keywords = "Delivery, Nanoparticles, Polyanhydrides, Stability, Therapeutic antibodies",
author = "Carrillo-Conde, {Brenda R.} and Darling, {Ross J.} and Seiler, {Steven J.} and Ramer-Tait, {Amanda E.} and Wannemuehler, {Michael J.} and Balaji Narasimhan",
year = "2015",
month = "3",
day = "4",
doi = "10.1016/j.ces.2014.08.015",
language = "English (US)",
volume = "125",
pages = "98--107",
journal = "Chemical Engineering Science",
issn = "0009-2509",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Sustained release and stabilization of therapeutic antibodies using amphiphilic polyanhydride nanoparticles

AU - Carrillo-Conde, Brenda R.

AU - Darling, Ross J.

AU - Seiler, Steven J.

AU - Ramer-Tait, Amanda E.

AU - Wannemuehler, Michael J.

AU - Narasimhan, Balaji

PY - 2015/3/4

Y1 - 2015/3/4

N2 - Passive administration of antibodies (e.g., anti-serum or monoclonal antibodies) can be successfully used as treatments for infectious agents (e.g., human cytomegalovirus, HIV), chronic inflammation (e.g., anti-TNF), cancer (e.g., anti-HER2, anti-VEGF, anti-CD20), toxins (e.g., anti-ricin), and age-related diseases such as macular degeneration (e.g., anti-VEGF). As with the development of proteinaceous pharmaceuticals, one of the most challenging obstacles facing passive immunotherapies is the physical and the chemical instabilities of the antibodies, which invariably leads to loss of biological activity. In order to avoid these problems, appropriate delivery vehicles need to be designed that minimize the degradation, maximize the in vivo activity, and provide controlled release of the encapsulated biologically active protein. In this study, polyanhydride nanoparticles were used for the delivery of stable and biologically active therapeutic antibodies. Tetanus antitoxin and anti-TNF-α monoclonal antibodies were encapsulated and released from polyanhydride nanoparticles. The nanoparticles provided the ability to control antibody release kinetics and, additionally, preserved antibody functionality and bioactivity upon synthesis and release. In particular, amphiphilic polyanhydride nanoparticles demonstrated the best combination of characteristics compatible for anti-serum or monoclonal antibody preservation and release, making them ideal candidates for use as a delivery system for therapeutic antibodies.

AB - Passive administration of antibodies (e.g., anti-serum or monoclonal antibodies) can be successfully used as treatments for infectious agents (e.g., human cytomegalovirus, HIV), chronic inflammation (e.g., anti-TNF), cancer (e.g., anti-HER2, anti-VEGF, anti-CD20), toxins (e.g., anti-ricin), and age-related diseases such as macular degeneration (e.g., anti-VEGF). As with the development of proteinaceous pharmaceuticals, one of the most challenging obstacles facing passive immunotherapies is the physical and the chemical instabilities of the antibodies, which invariably leads to loss of biological activity. In order to avoid these problems, appropriate delivery vehicles need to be designed that minimize the degradation, maximize the in vivo activity, and provide controlled release of the encapsulated biologically active protein. In this study, polyanhydride nanoparticles were used for the delivery of stable and biologically active therapeutic antibodies. Tetanus antitoxin and anti-TNF-α monoclonal antibodies were encapsulated and released from polyanhydride nanoparticles. The nanoparticles provided the ability to control antibody release kinetics and, additionally, preserved antibody functionality and bioactivity upon synthesis and release. In particular, amphiphilic polyanhydride nanoparticles demonstrated the best combination of characteristics compatible for anti-serum or monoclonal antibody preservation and release, making them ideal candidates for use as a delivery system for therapeutic antibodies.

KW - Delivery

KW - Nanoparticles

KW - Polyanhydrides

KW - Stability

KW - Therapeutic antibodies

UR - http://www.scopus.com/inward/record.url?scp=85027926563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027926563&partnerID=8YFLogxK

U2 - 10.1016/j.ces.2014.08.015

DO - 10.1016/j.ces.2014.08.015

M3 - Article

AN - SCOPUS:85027926563

VL - 125

SP - 98

EP - 107

JO - Chemical Engineering Science

JF - Chemical Engineering Science

SN - 0009-2509

ER -